title: Re: The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials.
authors.forename: D
authors.initials: D
authors.lastname: Valenti
mesh_terms: D003888:Desensitization, Immunologic; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000628:therapy*